I am a clinician scientist, leading the ovarian and rare cancer laboratory at WEHI and working as a medical oncologist at the Peter MacCallum Cancer Centre, Royal Women’s and Royal Melbourne Hospitals.

My clinical expertise is in gynaecological cancers and coordinating care for patients with rare cancers. I have 25 years’ experience in clinical cancer genetics, working in Familial Cancer Clinics.

My laboratory focuses on making pre-clinical models in which to study drug resistance in rare gynaecological cancers. I set up the national WEHI Stafford Fox Rare Cancer Program in order to facilitate the study of many rare cancer types which are poorly researched. I set up the Australian Rare Cancer Portal so that expert rare cancer care and research could be streamlined for individuals, no matter where they live.

I believe that involving the community in research enhances the purpose of our research and magnifies the benefits of what we do.


Selected publications from Prof Clare Scott

Ho GW^, Kyran EL^, Bedo J^, Wakefield MJ^, Ennis DP, Mirza HB, Vandenberg CV, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey U-M, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV, Cooke SL, on behalf of the Scottish Genomes Partnership, Ratnayake G, McNallyO, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Weroha J, Bowtell DD, McNeish IA#, Papenfuss AT#, SCOTT CL# and Barker HE#*. Ovarian carcinosarcoma genomics and preclinical models enable identification of eribulin as an effective treatment option for this aggressive cancer. Cancer Research. 2022. Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. PMID: 36206301. ^joint first authors, #joint senior authors

Nesic K#, Kondrashova O#, Hurley R, McGehee C, Vandenberg CM, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DD. Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A#, Wakefield MJ# and SCOTT CL#. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma. Cancer Research. 2021. 81(18):4709-472

Lee CK, Friedlander ML, Tjokrowidjaja A, Lederman JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, SCOTT CL, on behalf of the Gynecologic Cancer InterGroup Meta-analysis Committee. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive recurrent ovarian cancer: A meta-analysis. Cancer. 2021. Jul 15. 127(14): 2432-2441.

Cheasley D†, Wakefield MJ†, Ryland G†, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew Y-E, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kaufmann SH, Kalli KR, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, MacNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, de Cunha Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC*, SCOTT CL*, Campbell IG*, Gorringe KL*. The Molecular Origin and Taxonomy of Mucinous Ovarian Carcinoma. Nature Communications. 2019. 10(1):3935. †joint first authors, *joint senior authors.

Kondrashova* O, Topp M*,Monique, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, Australian Ovarian Cancer Study, DeFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A*, Wakefield MJ*, SCOTT CL*. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications. 2018. 9(1):3970. *equal contribution

Kondrashova O*, Nguyen M*, Shield-Artin K*, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O’Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K*, SCOTT CL*. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017 Jun 6 PMID: 28588062. *equal contribution

Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, SCOTT CL. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017. 145(1):130-136. PMID: 28162234

Swisher EM*, Lin KK*, Oza AM, SCOTT CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O’Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinumsensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 18(1):75-87. PMID: 27908594 *equal contribution.

Topp M, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield M, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular Oncol 2014. 8(3):656-68. PMID: 24560445

Kerr JB#, Hutt KJ#, Michalak EM#, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL *, Findlay JK*, Strasser A*. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require Tap63-mediated induction of Puma and Noxa. Mol Cell. 2012.;48(3):343-52. #joint first author, *joint senior author. Cover Image. PMID: 23000175

Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA. Targeting DNA repair: the genome as a potential biomarker. J Pathol. 2018, 244(5): 586-597. PMID: 29282716

Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: Recent advances and future developments. J Clin Oncol. 2015. 33(12):1397-406. PMID: 25779564

Lodhia K, Hadley H, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta. Rev on Cancer 2015. 1855(2):223-234. PMID: 25783201

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.